Outputs (3)

Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial (2023)
Journal Article
Abhishek, A., Peckham, N., Pade, C., Gibbons, J. M., Cureton, L., Francis, A., Barber, V., Williams, J. A. E., Appelbe, D., Eldridge, L., Julier, P., Altmann, D. M., Bluett, J., Brooks, T., Coates, L. C., Rombach, I., Semper, A., Otter, A., Valdes, A. M., Nguyen-Van-Tam, J. S., …Study investigators, V. (2024). Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial. The Lancet Rheumatology, 6(2), E92-E104. https://doi.org/10.1016/S2665-9913%2823%2900298-9

Background
Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improv... Read More about Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial.

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial (2023)
Journal Article
Abhishek, A., Peckham, N., Pade, C., Gibbons, J. M., Cureton, L., Francis, A., Barber, V., Williams, J. A. E., Appelbe, D., Eldridge, L., Julier, P., Altmann, D. M., Bluett, J., Brooks, T., Coates, L. C., Rombach, I., Semper, A., Otter, A., Valdes, A. M., Nguyen-Van-Tam, J. S., …Cook, J. A. (2023). Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial. The Lancet Rheumatology, 6(2), e92-e104. https://doi.org/10.1016/s2665-9913%2823%2900298-9

Background: Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improv... Read More about Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.

How people with knee pain understand why their pain changes or remains the same over time: A qualitative study (2023)
Journal Article
Walsh, D. A., Rathbone, J., Akin-Akinyosoye, K., Fernandes, G. S., Valdes, A. M., McWilliams, D. F., Zhang, W., Doherty, M., Hancox, J. E., Vedhara, K., das Nair, R., & Ferguson, E. (2023). How people with knee pain understand why their pain changes or remains the same over time: A qualitative study. Osteoarthritis and Cartilage Open, 5(2), Article 100345. https://doi.org/10.1016/j.ocarto.2023.100345

Objectives
Guidelines recommend knee osteoarthritis pain management based on biopsychosocial mechanisms. Treatment adherence and effectiveness may be affected if there is a mismatch between patient perspectives and treatment focus. We therefore exam... Read More about How people with knee pain understand why their pain changes or remains the same over time: A qualitative study.